USE OF PROMYELOCYTIC LEUKEMIA 1 (PML-1) PROTEIN IN PREPARATION OF DRUG FOR INHIBITING CYTOKINE STORM

Abstract: the present disclosure provides use of a promyelocytic leukemia 1 (pml-1) protein in preparation of a drug for inhibiting a cytokine storm, and belongs to the technical field of biomedicine. the present disclosure further provides use of a pml-1 protein and/or a product expressing the pml-1 protein in preparation of a drug for inhibiting a cytokine storm. in the present disclosure, the pml-1 protein and/or the product expressing the pml-1 protein can significantly inhibit the expression of proteins tab1, tak1, and p-tak1 and inhibit inflammatory cytokines tnf-�, il-1�, mip-1�, il-6, il-8, and mcp-1 in an inflammatory signaling pathway, thereby inhibiting the cytokine storm. the pml-1 protein can be directly used for the treatment of inflammations and related diseases. compared with traditional chemical anti-inflammatory drugs, the protein shows more significant curative effect, stronger specificity, lower toxicity, smaller side effects, and clearer biological functions, exhibiting broad application prospects.

Inventor(s): Fubing SHEN, Dai SHEN, Mengling LIU

CPC Classification: C07K14/435 (from animals; from humans)

Search for rejections for patent application number 20250230202